Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
A pharmacy in Melbourne generates 2.1M AUD-6.3M AUD AUD revenue, with net margin of 8 %. Typical mix: 75-85 % prescription drugs (regulated margin), 15-25 % OTC/wellness (free margin 35-45 %).
Dominant profile: business · etudiante
Melbourne (Victoria, Australia) has about 5.1M inhabitants and shows dense business fabric (HQs, B2B services, professionals), and large student population (~15-25 % of residents) driving low-cost and late-night demand. For a pharmacy project, this means a high average ticket and a setup cost above national by 50 %.
Local purchasing power and lead density allow targeting the high end of the revenue range from year 2. Concretely, initial investment calibrated for Melbourne ranges from 1.2M AUD to 5.3M AUD, and Year 1 target revenue sits between 2.1M AUD and 6.3M AUD — a range that already factors in the local coefficients of this city (+50% vs average on costs, +40% vs average on purchasing power).
Competitive density: high (dense supply, segmentation required).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 2.1M AUD → 6.3M AUD | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Melbourne, Australia (cost +50% vs average, income +40% vs average).
This page combines multiple data sources for a factual analysis calibrated on Melbourne.
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.